{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:28:43Z","timestamp":1787243323532,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy (nICT) is a novel and promising therapy model for locally advanced esophageal squamous cell carcinoma.The objective of this study aimed to assessed the impact of additional neoadjuvant immunotherapy on patients\u2019 short-term outcomes, particularly the incidence of anastomotic leakage (AL) and pathological response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with locally advanced esophageal squamous cell carcinoma who received neoadjuvant chemotherapy (nCT)\/ nICT combination with radical esophagectomy were enrolled from three medical centers in China. The authors used propensity score matching (PSM, ration:1:1, caliper=0.01) and inverse probability processing weighting (IPTW) to balance the baseline characteristics and compare the outcomes. Conditional logistic regression and weighted logistic regression analysis were used to further evaluate whether additional neoadjuvant immunotherapy would increase the risk of postoperative AL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 331 patients getting partially advanced ESCC receiving nCT or nICT were enrolled from three medical centers in China. After PSM\/IPTW, the baseline characteristics reached an equilibrium between the two groups. After matching, there were no significant difference in the AL incidence between the two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.68, after PSM;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.97 after IPTW), and the incidence of AL in the two groups was 15.85 versus 18.29%, and 14.79 versus 15.01%, respectively. After PSM\/IPTW, both groups were similar in pleural effusion and pneumonia. After IPTW, the nICT group had a higher incidence of bleeding (3.36 vs. 0.30%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.01), chylothorax (5.79 0.30%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001), and cardiac events (19.53 vs. 9.20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.04). recurrent laryngeal nerve palsy (7.85 vs. 0.54%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.003). After PSM, both groups were similar in palsy of the recurrent laryngeal nerve (1.22 vs. 3.66%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.31) and cardiac events (19.51 vs. 14.63%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.41). Weighted logistic regression analysis showed that additional neoadjuvant immunotherapy was not responsible for AL (OR=0.56, 95% CI: [0.17, 1.71], after PSM; 0.74, 95% CI: [0.34,1.56], after IPTW). The nICT group had dramatically higher pCR in primary tumor than the nCT group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.003, PSM;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.005, IPTW), 9.76 versus 28.05% and 7.72 versus 21.17%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Additional neoadjuvant immunotherapy could benefit pathological reactions without increasing the risk of AL and pulmonary complications. The authors require further randomized controlled research to validate whether additional neoadjuvant immunotherapy would make a difference in other complications, and determine whether pathologic benefits could translate into prognostic benefits, which would require longer follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000000487","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:03:16Z","timestamp":1686830596000},"page":"2168-2178","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study"],"prefix":"10.1097","volume":"109","author":[{"given":"Zhinuan","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Fujian Medical University, Fuzhou"},{"name":"Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, The Affiliated Hospital of Putian University"},{"name":"Department of Cardiothoracic Surgery, Putian Pulmonary Hospital, Putian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Cai","sequence":"additional","affiliation":[{"name":"Fujian Medical University, Fuzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunkui","family":"Ke","sequence":"additional","affiliation":[{"name":"Fujian Medical University, Fuzhou"},{"name":"Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbiao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, The Affiliated Hospital of Putian University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqiang","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"},{"name":"Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fujian Province University"},{"name":"Key Laboratory of Ministry of Education for Gastrointestinal Cancer"},{"name":"Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"R1-20250830","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J"},{"key":"R2-20250830","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"key":"R3-20250830","doi-asserted-by":"crossref","first-page":"101183","DOI":"10.1016\/j.eclinm.2021.101183","article-title":"Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: a network meta-analysis","volume":"42","author":"Fan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R4-20250830","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"R5-20250830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"key":"R6-20250830","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250830","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.21037\/atm-21-5381","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"R8-20250830","doi-asserted-by":"crossref","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"R9-20250830","doi-asserted-by":"crossref","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R10-20250830","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"R11-20250830","doi-asserted-by":"crossref","first-page":"e2239778","DOI":"10.1001\/jamanetworkopen.2022.39778","article-title":"Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis","volume":"5","author":"Ge","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R13-20250830","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10388-021-00899-x","article-title":"Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching","volume":"19","author":"Hong","year":"2022","journal-title":"Esophagus"},{"key":"R14-20250830","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: Strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R15-20250830","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2559.2005.02176.x","article-title":"Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"47","author":"Ryan","year":"2005","journal-title":"Histopathology"},{"key":"R16-20250830","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST Guideline (Version 1. 1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R17-20250830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"R18-20250830","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J Comp Eff Res"},{"key":"R19-20250830","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1245\/s10434-017-5827-1","article-title":"Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma","volume":"24","author":"Anderegg","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R20-20250830","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister","year":"2011","journal-title":"Eur J Cancer"},{"key":"R21-20250830","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejso.2015.03.226","article-title":"Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation","volume":"41","author":"Klevebro","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R22-20250830","doi-asserted-by":"crossref","first-page":"e0202185","DOI":"10.1371\/journal.pone.0202185","article-title":"Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: a meta-analysis based on clinical trials","volume":"13","author":"Zhao","year":"2018","journal-title":"PLoS One"},{"key":"R23-20250830","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ijrobp.2016.11.054","article-title":"Influence of the extent and dose of radiation on complications after neoadjuvant chemoradiation and subsequent esophagectomy with gastric tube reconstruction with a cervical anastomosis","volume":"97","author":"Ko\u00ebter","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20250830","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","article-title":"Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors","volume":"106","author":"Bott","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"R25-20250830","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jtcvs.2020.11.106","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer","volume":"161","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R26-20250830","doi-asserted-by":"crossref","first-page":"970534","DOI":"10.3389\/fimmu.2022.970534","article-title":"Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching","volume":"13","author":"Jing","year":"2022","journal-title":"Front Immunol"},{"key":"R27-20250830","doi-asserted-by":"crossref","first-page":"953229","DOI":"10.3389\/fimmu.2022.953229","article-title":"Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20250830","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12957-023-02915-z","article-title":"Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma","volume":"21","author":"Cheng","year":"2023","journal-title":"World J Surg Oncol"},{"key":"R29-20250830","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/SLA.0000000000005533","article-title":"Real-world evaluation of the efficacy of neoadjuvant dcf over cf in esophageal squamous cell carcinoma: propensity score matched analysis from 85 authorized institutes for esophageal cancer in japan","volume":"278","author":"Matsuda","year":"2023","journal-title":"Ann Surg"},{"key":"R30-20250830","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/1759-7714.14795","article-title":"Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma","volume":"14","author":"Yang","year":"2023","journal-title":"Thorac Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:03:21Z","timestamp":1756577001000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000487","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"2023-03-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}